Retatrutide in Australia
What retatrutide means for Australians
Obesity has overtaken tobacco as Australia's number one modifiable risk factor for disease. Retatrutide could be the most significant development in decades — here is why.
A growing national crisis
Australia’s healthcare system already spends billions every year managing obesity-related conditions — and the rate is forecast to keep rising with no sign of slowing. For millions of Australians who have struggled with their weight through diet, exercise and existing medications, retatrutide may represent the most powerful medical option ever developed.
0.0%
of Australian adults are overweight or obese (2026 estimate)
0%
of Australian adults are classified as obese (BMI ≥ 30)
0%
have severe obesity (BMI ≥ 35)
0
deaths in 2024 attributable to overweight and obesity — 10% of all deaths
0.0%
of Australia's total burden of disease is driven by obesity
0+
downstream diseases are driven by obesity, from diabetes to certain cancers
Where does Australia stand right now?
January 2026 — Wegovy joins the PBS
The Australian Federal Government added Wegovy (semaglutide) to the Pharmaceutical Benefits Scheme for individuals with severe obesity or cardiovascular history — a landmark moment for medical weight-loss treatment in Australia.
2027 — Eli Lilly files for approval
Eli Lilly plans to file retatrutide for regulatory approval in 2027. Retatrutide would represent the next generation of this treatment — significantly more powerful and broader in its benefits than anything currently available.
Following — TGA review
The Therapeutic Goods Administration would then review retatrutide for the Australian market. No date is guaranteed — but based on current timelines, the earliest realistic availability would be late 2027 or 2028.
Who could this help?
A medication capable of delivering surgical-level weight loss — while simultaneously improving blood sugar, joint pain, sleep apnoea and cardiovascular risk — could be transformative for Australians who:
Have struggled with weight for years despite diet and exercise
Live with type 2 diabetes, sleep apnoea, or joint pain
Are not candidates for — or wish to avoid — bariatric surgery
Want access to the most advanced metabolic medicine available
…retatrutide could be the most significant development in decades. Sign up below to follow its progress to Australia.
Stay informed
Be first to know when retatrutide reaches Australia.
Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:
- The latest clinical trial results and news from Eli Lilly
- Updates on TGA regulatory progress in Australia
- How and where to access retatrutide when it becomes available
- A direct link to a trusted source to learn more
